TP53 and colorectal carcinoma: To investigate potential sex-based disparities in clinical outcomes and treatment exposure, AI-HOPE-TP53 was queried to compare survival between male and female CRC patients with TP53 pathway alterations treated with FOLFOX chemotherapy.